IE 11 is a very old Browser and it`s not supported on this site

3. Other information required by law 

3.1 Name, legal form and registered office

BB Biotech AG is a limited company according to the Swiss Code of Obligation and has its registered office at Schwertstrasse 6 in Schaffhausen.

3.2 Declaration of number of full-time equivalents

The number of full-time equivalents did not exceed 10 in the calendar year 2020 (2019: below 10).

3.3 Investments

Investments of BB Biotech AG comprise, in the business years 2020 and 2019, the following subsidiaries:

Company

 

Capital in CHF 1 000

 

Capital and voting interest in %

Biotech Focus N.V., Curaçao

 

11

 

100

Biotech Growth N.V., Curaçao

 

11

 

100

Biotech Invest N.V., Curaçao

 

11

 

100

Biotech Target N.V., Curaçao

 

11

 

100

3.4 Treasury shares (balances and change)

Treasury shares are partly held by the Company directly and partly by its 100% subsidiary Biotech Target N.V. indirectly.

 

 

BB Biotech AG

 

Biotech Target N.V.

 

Total

Balance at January 1, 2019

 

 

 

Balance at December 31, 2019

 

 

 

 

 

 

 

 

 

 

Purchases Biotech Target N.V. at an average price of CHF 71.83

 

 

114 998

 

114 998

Sales Biotech Target N.V. at an average price of CHF 60.18

 

 

(336)

 

(336)

Balance at December 31, 2020

 

 

114 662

 

114 662

3.5 Audit fees

The audit fees comprise the following (in CHF):

 

 

2020

 

2019

Audit fees

 

120 000

 

120 000

Audit-related fees

 

2 800

 

2 000

 

 

122 800

 

122 000

3.6 Commitments and contingencies

The Company had no commitments or other off-balance sheet transactions open at December 31, 2020 (2019: none).

The operations of the Company are affected by legislative, fiscal and regulatory developments for which provisions are made where deemed necessary. The Board of Directors concludes that as at December 31, 2020, no proceedings existed which could have any material effect on the financial position of the Company (2019: none).

3.7 Subsequent events

There have been no events subsequent to December 31, 2020, which would affect the 2020 financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer